581 related articles for article (PubMed ID: 33022803)
21. HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management.
Nahon P; Layese R; Cagnot C; Asselah T; Guyader D; Pol S; Pageaux GP; De Lédinghen V; Ouzan D; Zoulim F; Audureau E;
Cancer Prev Res (Phila); 2021 May; 14(5):581-592. PubMed ID: 33608313
[TBL] [Abstract][Full Text] [Related]
22. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.
Cordero-Ruiz P; Carmona-Soria I; Rodríguez-Téllez M; Caunedo-Alvarez A; Quezada-Pacheco RH; Flores-Cucho A; Romero-Gómez M; Vilches-Arenas Á
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):792-799. PubMed ID: 28445251
[TBL] [Abstract][Full Text] [Related]
23. Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Who Achieved Sustained Virologic Response.
Toyoda H; Tada T; Yasuda S; Mizuno K; Ito T; Kumada T
Clin Infect Dis; 2020 Mar; 70(6):1208-1214. PubMed ID: 31056696
[TBL] [Abstract][Full Text] [Related]
24. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
[TBL] [Abstract][Full Text] [Related]
25. Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication.
Lu MY; Yeh ML; Huang CI; Wang SC; Tsai YS; Tsai PC; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Chen SC; Huang CF; Huang JF; Dai CY; Chuang WL; Yu ML
World J Gastroenterol; 2022 Jan; 28(1):140-153. PubMed ID: 35125824
[TBL] [Abstract][Full Text] [Related]
26. GES: A validated simple score to predict the risk of HCC in patients with HCV-GT4-associated advanced liver fibrosis after oral antivirals.
Shiha G; Waked I; Soliman R; Elbasiony M; Gomaa A; Mikhail NNH; Eslam M
Liver Int; 2020 Nov; 40(11):2828-2833. PubMed ID: 32946647
[TBL] [Abstract][Full Text] [Related]
27. Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV).
Quaranta MG; Cavalletto L; Russo FP; Calvaruso V; Ferrigno L; Zanetto A; Mattioli B; D'Ambrosio R; Panetta V; Brancaccio G; Raimondo G; Brunetto MR; Zignego AL; Coppola C; Iannone A; Biliotti E; Rosselli Del Turco E; Massari M; Licata A; Barbaro F; Persico M; Morisco F; Pompili M; Cerini F; Puoti M; Santantonio T; Craxì A; Kondili LA; Chemello L; On Behalf Of Piter Collaborating Investigators
Viruses; 2024 Apr; 16(5):. PubMed ID: 38793565
[TBL] [Abstract][Full Text] [Related]
28. Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals.
Huang CF; Yeh ML; Huang CI; Liang PC; Lin YH; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Yu ML
Hepatol Int; 2018 Nov; 12(6):544-551. PubMed ID: 30426395
[TBL] [Abstract][Full Text] [Related]
29. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH
J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684
[TBL] [Abstract][Full Text] [Related]
31. Serum sphingolipids predict de novo hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virologic response.
Mücke VT; Thomas D; Mücke MM; Waidmann O; Zeuzem S; Sarrazin C; Pfeilschifter J; Vermehren J; Finkelmeier F; Grammatikos G
Liver Int; 2019 Nov; 39(11):2174-2183. PubMed ID: 31207039
[TBL] [Abstract][Full Text] [Related]
32. Comparing Predictability of Non-invasive Tools for Hepatocellular Carcinoma in Treated Chronic Hepatitis C Patients.
Liu YC; Cheng YT; Chen YC; Hsieh YC; Jeng WJ; Lin CY; Chien RN; Tai DI; Sheen IS
Dig Dis Sci; 2023 Jan; 68(1):323-332. PubMed ID: 35895234
[TBL] [Abstract][Full Text] [Related]
33. Prediction of Hepatocellular Carcinoma by Liver Stiffness Measurements Using Magnetic Resonance Elastography After Eradicating Hepatitis C Virus.
Kumada T; Toyoda H; Yasuda S; Sone Y; Ogawa S; Takeshima K; Tada T; Ito T; Sumida Y; Tanaka J
Clin Transl Gastroenterol; 2021 Apr; 12(4):e00337. PubMed ID: 33888672
[TBL] [Abstract][Full Text] [Related]
34. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
[TBL] [Abstract][Full Text] [Related]
35. Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients.
Wang HM; Hung CH; Lu SN; Chen CH; Lee CM; Hu TH; Wang JH
Liver Int; 2013 May; 33(5):756-61. PubMed ID: 23405889
[TBL] [Abstract][Full Text] [Related]
36. Late development of hepatocellular carcinoma after viral clearance in patients with chronic hepatitis C: A need for continual surveillance.
Tong MJ; Theodoro CF; Salvo RT
J Dig Dis; 2018 Jul; 19(7):411-420. PubMed ID: 29889353
[TBL] [Abstract][Full Text] [Related]
37. Liver stiffness-based score at sustained virologic response predicts liver-related complications after eradication of hepatitis C virus.
Kuo YH; Kee KM; Hung CH; Lu SN; Hu TH; Chen CH; Wang JH
Kaohsiung J Med Sci; 2022 Mar; 38(3):268-276. PubMed ID: 34687140
[TBL] [Abstract][Full Text] [Related]
38. Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment.
Ogawa E; Furusyo N; Nomura H; Dohmen K; Higashi N; Takahashi K; Kawano A; Azuma K; Satoh T; Nakamuta M; Koyanagi T; Kato M; Shimoda S; Kajiwara E; Hayashi J;
Aliment Pharmacol Ther; 2018 Jan; 47(1):104-113. PubMed ID: 29035002
[TBL] [Abstract][Full Text] [Related]
39. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma.
Piñero F; Mendizabal M; Ridruejo E; Herz Wolff F; Ameigeiras B; Anders M; Schinoni MI; Reggiardo V; Palazzo A; Videla M; Alonso C; Santos L; Varón A; Figueroa S; Vistarini C; Adrover R; Fernández N; Perez D; Tanno F; Hernández N; Sixto M; Borzi S; Bruno A; Cocozzella D; Soza A; Descalzi V; Estepo C; Zerega A; de Araujo A; Cheinquer H; Silva M;
Liver Int; 2019 Jun; 39(6):1033-1043. PubMed ID: 30636361
[TBL] [Abstract][Full Text] [Related]
40. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N
Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]